Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Equity Income (2022 - 2024)

Amphastar Pharmaceuticals (AMPH) has 3 years of Equity Income data on record, last reported at -$573000.0 in Q1 2024.

  • For Q1 2024, Equity Income rose 27.01% year-over-year to -$573000.0; the TTM value through Dec 2024 reached -$573000.0, up 71.08%, while the annual FY2024 figure was -$573000.0, 71.08% up from the prior year.
  • Equity Income reached -$573000.0 in Q1 2024 per AMPH's latest filing, down from -$505000.0 in the prior quarter.
  • Across five years, Equity Income topped out at -$57000.0 in Q4 2022 and bottomed at -$785000.0 in Q1 2023.
  • Average Equity Income over 3 years is -$414555.6, with a median of -$390000.0 recorded in 2023.
  • Peak YoY movement for Equity Income: plummeted 785.96% in 2023, then rose 27.01% in 2024.
  • A 3-year view of Equity Income shows it stood at -$57000.0 in 2022, then tumbled by 785.96% to -$505000.0 in 2023, then decreased by 13.47% to -$573000.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Equity Income were -$573000.0 in Q1 2024, -$505000.0 in Q4 2023, and -$390000.0 in Q3 2023.